When the fasting GLP-1 concentration is comparatively high to begin with, by preventing the proteolytic degradation of GLP-1 with DPP-IV inhibition, considerable increase in GLP-1 responses during the OGTT ensues leading to significant stimulation of insulin secretion and reduction in plasma glucose
Constipation may remain a long-term issue for some manageable with adequate fibre, water, and movement
Thank you to the FDA for sharing this valuable update
In an evidence-based approach, the key points contributing to this consensus with respect to the clinical impact and benefits of GLP-1 RAs and their use in special populations are as follows: Clinical impact of GLP-1 RAs: GLP-1 RAs improve glucose homeostasis by enhancing glucose-dependent insulin secretion, by suppressing inappropriately elevated glucagon levels, both in fasting and postprandial states (Grade A
Hox genes in animal development, MAD box genes in plant development) and likely lies at the heart of network evolution more broadly (WAGNER 2008)
Ask about the active ingredient, expected titration, injection training, gastrointestinal effects, glucose monitoring, pregnancy considerations, and what to do if side effects interfere with meals or hydration